Unpacking Lysosomal Storage: New Insights Drive Parkinson’s Drug Development
This article was originally published in Start Up
Executive Summary
Investors and dealmakers are using recent discoveries about convergences between Gaucher’s disease and Parkinson’s in the lysosome to generate new therapeutic programs. Start-up Lysosomal Therapeutics thinks that the rare disorder can serve as a model system for developing new drugs to increase lysosomal function as a way to treat Parkinson’s disease and possibly other neurodegenerative disorders.
You may also be interested in...
Will Yeast Lead The Way To Parkinson’s Disease Drugs? An Interview With Tony Coles Of Yumanity Therapeutics
The duo behind Yumanity brings to it multiple successes measured by basic science discoveries, new drugs for patients, and billions made for investors. Can they do it again with their novel approach for discovering neurodegenerative disease drugs?
Still Hopeful About Migalastat, Amicus Also Pursuing Optimized Enzyme Replacement Therapies
Amicus’ most promising candidate would improve upon Sanofi/Genzyme’s Pompe disease drug Lumizyme, but closer to the clinic is a program to combine Fabry disease candidate migalastat with an enzyme replacement therapy obtained in last year’s buyout of Callidus.
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.